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A new version of the EQ‐5D, the EQ‐5D‐5L, is available. The aim of this study is
to produce a value set to support use of EQ‐5D‐5L data in decision‐making.
The study design followed an international research protocol. Randomly
selected members of the English general public completed 10 time trade‐off
and 7 discrete choice experiment tasks in face‐to‐face interviews.
A 20‐parameter hybrid model was used to combine time trade‐off and discrete
choice experiment data to generate values for the 3,125 EQ‐5D‐5L health states.
Valuation data are available for 996 respondents. Face validity of the data has
been demonstrated, with more severe health states generally given lower
values. Problems with pain/discomfort and anxiety/depression received the
greatest weight. Compared to the existing EQ‐5D‐3L value set, there are consid-
erably fewer “worse than dead” states (5.1%, compared with over one third),
and the minimum value is higher. Values range from −0.285 (extreme prob-
lems on all dimensions) to 0.950 (for health states 11211 and 21111).
Results have important implications for users of the EQ‐5D‐5L both in England
and internationally. Quality‐adjusted life year gains from interventions seeking
to improve very poor health may be smaller using this value set and may previ-
ously have been overestimated.
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Health care decisions are made under uncertainty, whereby any decision may have a range of different outcomes. To
make the “best” decision, potential outcomes need ordering and valuing. Such decisions are made both at the individual
level, such as choosing the optimal treatment for a patient, and at the national level, such as choosing how to allocate
resources between treatments for different patient groups and across different health conditions.
Clinical decisions often affect patients' health‐related quality of life (HRQL). Evidence on patients' HRQL can be
obtained using patient‐reported outcome (PRO) measures. These may be condition specific or generic (see Fayers and
Machin, 2016, and Longworth et al., 2014, for further information). Condition‐specific PROs focus on specific health- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 DEVLIN ET AL.problems and aim to provide detailed information about the impacts of the condition, disregarding problems that are
atypical for the condition. Generic PROs aim to cover a more general spectrum of health problems and are designed
to be applicable for any health condition. They can capture comorbidities and allow comparisons with population norms.
Evidence obtained from generic measures can be used to compare both the impact of health problems and the benefits
offered by treatments across different patient populations and disease areas. This makes these data particularly useful for
informing decisions made by health care professionals, commissioners, regulators, health technology assessment bodies
(such as the National Institute for Health and Care Excellence [NICE]), payers, and budget holders.
The EQ‐5D is the most widely used generic PRO questionnaire internationally (Devlin & Brooks, 2017; Richardson,
McKie, & Bariola, 2014). It is the instrument recommended by NICE for evidence submitted to its technology appraisal
process (NICE, 2013). It has also proved useful in population health surveys and in the English National Health Service
(NHS) patient‐reported outcome measures programme (Devlin & Appleby, 2010). The EQ‐5D asks patients to indicate
whether they have no, some, or extreme problems on each of five dimensions of health: mobility, self‐care, usual
activities, pain/discomfort, and anxiety/depression.
The EQ‐5D is a valid and reliable measure in many disease areas (Janssen, Lubetkin, Sekhobo, & Pickard, 2011;
Pickard, Wilke, Lin, & Lloyd, 2007; Wailoo, David, & Tosh, 2010). However, there have been concerns that three
response options for each dimension may not adequately capture milder health problems experienced by patients, and
smaller changes between different health states. A new version of the instrument, the EQ‐5D‐5L, was developed to
improve sensitivity and to standardise the language used across dimensions (Herdman et al., 2011). The EQ‐5D‐5L
comprises the same five dimensions, but increases the available response options (levels) from three to five (no, slight,
moderate, severe, and extreme problems/unable to)—see Figure 1. The five dimensions and five levels of the EQ‐5D‐5L
describe 3,125 (55) unique health states, compared to the 243 (35) described by the EQ‐5D.
The EQ‐5D‐5L is rapidly being incorporated into routine data collection in clinical settings, clinical trials and
population health surveys, such as the GP patient survey (NHS, 2016) and the Health Survey for England (Fuller,
Mindell, & Prior, 2016). It is also used in local initiatives. For example, the Cambridgeshire Community Services NHS
Trust collects EQ‐5D‐5L data to evaluate outcomes from rehabilitation services (Cambridgeshire Community ServicesFIGURE 1 The EQ‐5D‐5L descriptive system
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health, whereby every health state that patients might report on the EQ‐5D‐5L instrument can be summarised by a sin-
gle value. In order to be used in the calculation of quality‐adjusted life years (QALYs; a metric used in cost‐utility anal-
ysis that combines survival and HRQL), these values need to summarise how good or bad each health state is on a scale
anchored at 1 (full health) and 0 (a state equivalent to dead). Values less than 0 represent health states considered to be or
modelled as worse than dead. The values are based on the views of the general public who are asked to imagine living in
various health states and to respond to a series of structured questions designed to find out the importance to them of
different aspects of health. This approach follows the requirements of NICE (2013) and similar organisations (e.g.,
Australia's Pharmaceutical Benefits Advisory Committee, 2016, and the Canadian Agency for Drugs and Technologies
in Health, 2006) for the use of EQ‐5D‐5L data in decision‐making and reflects a belief that it is the views of the general
public—as taxpayers and potential users of health care—that should count, rather than simply those of patients (Neu-
mann, Ganiats, Russell, Sanders, & Siegel, 2017).
At the time of writing, 25 value sets for the (three‐level) EQ‐5D‐3L are available (Devlin & Brooks, 2017), a number of
which are summarised by Szende, Oppe, and Devlin (2007). The current U.K. EQ‐5D‐3L value set (Dolan, 1997)—which
was developed based on data collected in the early 1990s—has values that range from 1 for no problems on any dimen-
sion to −0.594 for the worst health state (Level 3 problems on each dimension). A number of limitations have been noted
with that value set. Among these are that approximately a third of health states described by the EQ‐5D‐3L were assigned
negative values, meaning those health states are valued as being worse than dead. Although this may reflect genuine
preferences, it is worth noting that the U.K. EQ‐5D‐3L values are rather unique in this respect: all other countries have
fewer worse than dead health states and higher minimum values. Another generic measure with a U.K. value set—the
SF‐6D (Brazier, Roberts, & Deverill, 2002)—includes no health states valued as worse than dead. Additionally, although
also common to other countries, any change in health away from full health to “some” problems, on any aspect of
health, results in a large fall in the overall value (of at least 0.12, meaning that the highest value for a health state describ-
ing at least some health problems is 0.88) on the 0 to 1 scale. The issues with the current EQ‐5D‐3L value set—particu-
larly those regarding the larger number of health states modelled as worse than dead and the large differences in utility
between adjacent levels—may be linked to features of the instrument (such as the labels used to describe different sever-
ity levels), the methods used to elicit preferences, and the modelling process used to derive value sets. Issues with the
modelling used in the U.K. EQ‐5D‐3L value set study have been raised in the literature (Hernández Alava, Wailoo, &
Ara, 2012). For example, it has been argued that the application of linear regression methods for modelling skewed data,
and the use of an N3 term (see below), extended the range of the utility scale. It also contributed to the distinctive two‐
group distribution often noted when applying the value set to patients' data (Parkin, Devlin, & Feng, 2016). The charac-
teristics of the EQ‐5D‐3L value set may have important implications for decisions being made in the NHS. For example,
NICE estimates of QALY gains from new treatments that restore patients with health problems to a state of full health
may be biased upwards, because they will be improving from a relatively low baseline.
To date, there have been no values specific to the (five‐level) EQ‐5D‐5L in England available to summarise patients'
data. Research has established the relationship between patients' self‐reported health on the EQ‐5D‐3L and on the
EQ‐5D‐5L, enabling EQ‐5D‐5L data collected from patients to be summarised using the EQ‐5D‐3L value set via a
“mapping algorithm” (van Hout et al., 2012). This provides an interim means of scoring EQ‐5D‐5L data, but perpetuates
the limitations of the EQ‐5D‐3L value set (Devlin, Tsuchiya, Buckingham, & Tilling, 2011; Devlin et al., 2013; Tilling,
Devlin, Tsuchiya, & Buckingham, 2010).
The aim of this study is to produce a value set for the EQ‐5D‐5L that can be used to support decision‐making in the
English NHS. The results will have international impact given that decisions made by NICE influence health technology
assessment decisions around the world (Hernandez‐Villafuerte, Garau, & Devlin, 2014). The study is relevant to
clinicians collecting PRO data from patients and to those using PRO data in health care decisions. It demonstrates the
relative importance placed on different types of health problems by people in England—and how that should be reflected
in priority setting.2 | METHODS
The research design and data collection followed a protocol developed by the EuroQol Group, a not‐for‐profit interna-
tional network of multidisciplinary researchers. The protocol was informed by an extensive programme of methodolog-
ical research investigating methods for valuing EQ‐5D‐5L health states (Oppe, Devlin, van Hout, Krabbe, & de Charro,
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concluded or are currently in progress.2.1 | Methods of eliciting preferences
The study used the EuroQol Valuation Technology (EQ‐VT) software, developed specifically for EQ‐5D‐5L value set
studies and administered using computer‐assisted personal interviews. Two stated preference methods were used to elicit
preferences: time trade‐off (TTO), an approach used in previous EQ‐5D valuation studies (Oppe et al., 2014) and accepted
by NICE as a “choice‐based” approach (NICE, 2013); and the discrete choice experiment (DCE), an approach that is
increasingly used to assess preferences for health states because of the relative simplicity of the tasks (Ryan, Gerard,
& Amaya‐Amaya, 2008). The two methods generate different and complementary preference data. TTO elicits a value
for each state with 1 and 0 defined as anchor points, whereas DCE generates binary data that allow for the derivation
of a scale of nonanchored relative values.
Each interview consisted of the following tasks (in order): self‐reported health using EQ‐5D‐5L, self‐reported health
on a 0–100 visual analogue scale; basic background questions (common to all value set studies administered via EQ‐VT);
a practice TTO task (involving the valuation of a simple health state that described requiring the use of a wheelchair); 10
TTO tasks; structured feedback questions regarding the TTO tasks; seven DCE tasks; structured DCE feedback questions;
an (optional) open‐ended comment box; and further England‐specific background questions.
In the TTO tasks, a composite approach was used that involved starting with the “conventional” TTO (Brazier,
Ratcliffe, Salomon, & Tsuchiya, 2017) for all health states and shifting to a “lead time” TTO when participants indicated
that they considered the health state to be worse than dead (Devlin et al., 2011; Devlin et al., 2013; Robinson & Spencer,
2006). The composite TTO approach is illustrated in Figure 2a,b. Evidence supporting this approach is reported by
Janssen, Oppe, Versteegh, and Stolk (2013). Figure 2a illustrates the TTO task for health states better than dead (i.e.,
those with a value between 0 and 1). The participant is asked to imagine living for 10 years from today in a given EQ‐
5D‐5L state, followed by death (Life B). The participant's value for that health state is then derived by identifying, using
an iterative process combining bisection and upward/downward titration approaches (Oppe, Rand‐Hendriksen, Shah,
Ramos‐Goñi, & Luo, 2016), the number of years in full health between 0 and 10 (Life A) they consider equivalent to that.
The more severe the health state described in Life B, the more years of full health the participant is assumed to be willing
to give up in Life A to avoid Life B. For very poor health states, all of the time in Life A may be traded off, indicating that
the value for the state is less than or equal to 0. Where this occurs, additional time in full health (lead time) is added to
both Lives A and B—see Figure 2b. This allows participants to trade‐off more time, reflecting how much worse than dead
they consider the health state to be (within the boundaries of the scale imposed by the task; Devlin et al., 2013).
The variant of lead time TTO used in this study involved a 20‐year time frame (10 years of lead time followed by
10 years in the health state under evaluation), yielding a minimum value of −1. No additional trade‐off questions were
asked of those who exhausted their lead time (Devlin et al., 2013). The iterative procedure used to seek the point of indif-
ference was based on an adaptation of that used in the U.K. EQ‐5D value set study (Dolan, 1997). Further details about
EQ‐VT and the iterative process used in the TTO tasks are provided by Oppe et al. (2014).
Each TTO task ends when the participant indicates that they consider Lives A and B to be “about the same.” At this
point of indifference, the implied value for health states better than dead is calculated by dividing the total number of
years in Life A (t) by 10 (the total number of years in Life B). This can be expressed as V = t/10, where V is the health
state value. For example, at the point of indifference shown in Figure 2a, the health state value would be 5/10 = 0.5. The
implied value for health states worse than dead is calculated by subtracting 10 (the number of years of lead time) from
the total number of years in Life A, then dividing by 10 (the total number of years in Life B minus the number of years of
lead time). This can be expressed as V = (t − 10)/10. The point of indifference shown in Figure 2b would suggest a value
of (5–10)/10 = −0.5. The maximum value is 1, achieved when the participant considers 10 years in the health state to be
as good as 10 years in full health. A value of 0 is given when the participant considers the health state to be no better and
no worse than dead. The minimum score of −1 (where all of the lead time is exhausted) is given when the participant
considers the prospect of living for 10 years in full health followed by 10 years in the health state to be worse than or
equivalent to a life lasting 0 years (i.e., dying now).
In each DCE task (Figure 3), participants were presented with a pair of health states (labelled A and B), with no
reference to the duration of the states, and asked to indicate which they considered to be “better” by clicking the
appropriate button. No indifference option was included.
FIGURE 2 (a) Example of time trade‐off valuation of health states better than dead (i.e., values ≥ 0). (b) Example of time trade‐off valuation
of health states worse than dead (i.e., values ≤ 0) [Colour figure can be viewed at wileyonlinelibrary.com]
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FIGURE 3 Example discrete choice
experiment task [Colour figure can be
viewed at wileyonlinelibrary.com]
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The TTO design included 86 states. Six health states—the worst state (55555) and the five mildest states (21111, 12111,
11211, 11121, and 11112) were selected a priori. The mild health states were included so that direct observations of these
would ensure that we could statistically distinguish minor problems from full health. These states were supplemented with
80 states selected using the design strategy described in Oppe and van Hout (2010). This design was generated by randomly
selecting 80 health states from the full fractional design minus the six health states noted above. An expected health state
value was assigned to each of the 86 states in the design on the basis of priors. Subsequently, a regression model was esti-
mated on the dataset to calculate predicted values for each health state. The strategy was “looped” until a design was iden-
tified with small differences between prior and predicted values. The 80 states were distributed over 10 blocks in such a way
that the full utility range would be covered within a block and all blocks would have the same mean utility. In the final
design, each block included eight health states unique to that block, plus state 55555 and one of the mild health states.
The DCE experimental design included 196 pairs randomly divided into 28 blocks identified using a Bayesian design.
The blocks were balanced in terms of their severity, as assessed by the level sum scores of the health states (see below).
None of the pairs in the DCE design included a health state that logically dominated the other (i.e., at least as good on all
five dimensions). Participants were randomly assigned to one of the 10 blocks of TTO tasks and to one of the 28 blocks of
DCE tasks. Block assignment, question order, and (in DCE) the left–right position of health states were all randomised.
The EQ‐5D‐5L valuation protocol (Oppe et al., 2014) suggests a target sample size of 1,000 participants. A previous
study (Janssen et al., 2013) found that 100 observations per health state resulted in a small standard error of mean health
state values between 0.01 (for mild states) and 0.06 (for poor states), which was considered sufficient. The number of
TTO tasks per participant was set to 10, resulting in a sample size of 1,000.2.3 | Data collection
Sample recruitment and interviewing was carried out by the market research company Ipsos MORI. A sample of 2,220
addresses from 66 primary sampling units across England was randomly selected based on postcode sectors using the
Post Office small user Postcode Address File. This includes all private residential accommodation in England (communal
establishments, such as prisons and care homes, were excluded). Thirty‐seven addresses were selected systematically
from an ordered list of all addresses within each sampling unit, ensuring that addresses were spread evenly across it.
Interviewers sent an advance letter and information sheet to each selected address, together with an unconditional
incentive of six first‐class stamps. In each selected dwelling unit, all individuals aged 18 years and over were listed in
alphabetical order by first name, and one was selected randomly using a selection grid with no substitutes permitted.
If the selected individual gave their informed consent to take part, they were interviewed in their own home. The
participant was in control of the computer (laptop) throughout the tasks, with the interviewer guiding them through
each step, following a script. The one‐to‐one setting allowed interviewers to provide detailed instruction and feedback
where appropriate (Shah, Lloyd, Oppe, & Devlin, 2013).
Forty‐eight interviewers were used, all of whom attended a full day briefing in which they were given intensive train-
ing on the methodology and study procedures by the research team. Interim data were monitored at the interviewer
level, at least weekly. If an interviewer was found to be generating unusual or poor quality data (defined using criteria
DEVLIN ET AL. 7based on expected data characteristics, given previous research (e.g., Shah et al., 2013), such as minimum task comple-
tion times), they were given additional training. No data were removed at this stage.2.4 | Piloting
The main study was preceded by a small pilot study (n = 49), undertaken in August 2012. The pilot sample was recruited
using quotas on age, gender, and working status rather than using the systematic approach described above. The aims of
the pilot were to test for technical issues with EQ‐VT, to test Ipsos MORI's procedures and methods of encouraging par-
ticipation, to seek interviewers' feedback on the preliminary script and other materials, to seek participants' feedback on
the interview, to examine basic properties of the data generated, and to identify ways to improve the interviewer training
process. The pilot was completed successfully, with no issues with EQ‐VT reported by participants or interviewers. Sev-
eral improvements were made as a result of the feedback received during piloting. These included refinement of the
interviewer script and improvements to the interviewer training process.2.5 | Methods of analysis
For both TTO and DCE, a range of descriptive analyses were conducted to assess data characteristics. For TTO, this
included examining the overall distribution of values and correlating average values for each health state with its level
sum score (a proxy for severity; e.g., the worst health state 55555 has a score of 5 + 5 + 5 + 5 + 5 = 25). Following the
approach of Janssen et al. (2013), face validity of the TTO data was assessed by checking for the expected negative rela-
tionship between level sum score and average observed value. Face validity of the DCE data was assessed by comparing
the proportion of participants choosing health state A with the difference in level sum scores between A and B, with the
implicit assumption that health states with lower level sum scores would be more likely to be chosen overall.
To generate the modelling dataset, we tested a range of possible exclusion criteria, reflecting alternative judgements
that might be made about the quality of the data. We wished to minimise exclusions but sought to omit data that were
clearly implausible. The final rules for the TTO data were to exclude (a) participants who gave all 10 health states the
same value (all health states cannot plausibly be given the same value given the severity range in each block) and (b)
participants who gave the worst state, 55555, a value that was no lower than the value they gave to the mildest health
state in their block. Both suggest either misunderstanding or lack of engagement.
No DCE data were excluded.
The EuroQol Group does not have a standard modelling protocol for the analysis of EQ‐5D‐5L valuation data, as dif-
ferent methods may be required to reflect the fact that the data characteristics are likely to vary across countries. The
modelling methods in this study therefore explicitly addressed the observed characteristics of the data (Feng, Devlin,
Shah, Mulhern, & van Hout, 2017). First, the minimum TTO value is bounded at −1 by design, so we allowed for the pos-
sibility of values lower than that using survival analysis approaches for treating censored data. Second, the maximum TTO
value is 1, again by design, so although there is an error distribution around observed values, that distribution is necessar-
ily asymmetric at 1, biasing the values for mild health states downwards. Thus, the values at 1 were also considered to be
censored. Third, there were some participants who used 0 as the minimum value for more than one health state (almost
always including health state 55555). This suggests that these participants were averse to giving negative TTO values.
Those values were considered to be censored at zero. Furthermore, some participants gave health state 55555 a value of
0 whilst giving multiple other health states a negative value. This in an example of a “logical inconsistency,” because
55555 is dominated by all other health states. Those values were censored at 0. See Feng et al. (2017) for further details.
Further, we observed that participants more often disagree about the value of health states that are further away from
full health, that is, the variance of TTO values increases for worse health states. Based on examinations of visual repre-
sentations of the valuation data at the individual participant level to identify common patterns, it was apparent that
different groups of participants differed in their use of the scale, resulting in substantially different slopes (i.e., the
relationships between disutility and health state severity). This could fundamentally be driven by the heterogeneity of
participants in their views about death. The effect of heterogeneity was explored using models that introduced a
parameter for the scale of disutility in health, which may differ between participants. The scale of disutility in health
was assumed to follow a multinomial distribution with probability density on a number of latent groups. Each of the
latent groups has its mean and variance for the distribution of the scale. In our analysis, we assessed the fit of models
with two to 10 latent groups using the deviance information criterion (DIC). We also accounted for heteroskedasticity
TABLE 1 Background characteristics of the sample
All participants (n = 996)a After exclusions (n = 912)a General populationb
N (%) N (%) %
Age
18–29 113 (11.3) 105 (11.5) 20.7
30–44 298 (29.9) 270 (29.6) 26.3
45–59 250 (25.1) 227 (24.9) 24.7
60–74 207 (20.8) 191 (20.9) 18.5
75+ 128 (12.9) 119 (13.0) 9.9
Gender
Male 405 (40.7) 372 (40.8) 49.2
Female 591 (59.3) 540 (59.2) 50.8
Economic activity
Employed or self‐employed 504 (51.2) 463 (50.8) 59.4
Retired 278 (28.2) 256 (28.1) 13.1
Student 20 (2.0) 19 (2.1) 8.8
Looking after home or family 83 (8.4) 73 (8.0) 4.2
Long‐term sick or disabled 48 (4.9) 42 (4.6) 3.9
Other/none of the above 52 (5.3) 47 (5.2) 10.6
Marital status
Never married 238 (24.2) 225 (24.7) 34.6
Married 466 (47.3) 434 (47.6) 46.6
Same‐sex civil partnership 2 (0.2) 2 (0.2) 0.2
Separatedc 37 (3.8) 32 (3.5) 2.7
Divorced 131 (13.3) 119 (13.0) 9.0
Widowedd 107 (10.9) 99 (10.9) 6.9
Prefer not to say 4 (0.4) 1 (0.1) N/A
Religion
Christian 636 (64.6) 575 (63.9) 59.4
Any other religion 60 (6.1) 53 (5.9) 8.7
No religion 281 (28.5) 266 (29.6) 24.7
Religion not stated 8 (0.8) 6 (0.7) 7.2
Ethnicity
White 900 (91.4) 832 (92.4) 85.4
Any other ethnic group 82 (8.3) 67 (7.4) 14.6
Prefer not to say 3 (0.3) 1 (0.1) N/A
Day‐to‐day limitations due to health problem or disability
Limited a lot 111 (11.3) 95 (10.6) 5.6e
Limited a little 158 (16.0) 144 (16.0) 7.1e
Not limited 716 (72.7) 661 (73.4) 87.3e
Education
Degree 211 (21.4) 201 (22.3) N/A
No degree 774 (78.6) 699 (77.7)
Main language spoken
English 920 (93.4) 847 (94.1) N/A
Any other language 65 (6.6) 53 (5.9)
Responsibility for children
Yes 350 (35.5) 314 (34.9) N/A
No 635 (64.5) 586 (65.1)
Experience of serious illness
In self 330 (33.1) 297 (32.6) N/A
In family 692 (69.5) 636 (69.7)
In caring for others 416 (41.8) 385 (42.2)
Self‐rated health using EQ‐5D‐5L
11111 474 (47.6) 437 (47.9) N/A
Any other health state 522 (52.4) 475 (52.1)
(Continues)
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TABLE 1 (Continued)
All participants (n = 996)a After exclusions (n = 912)a General populationb
N (%) N (%) %
Self‐rated health using EQ‐VAS
<80 334 (33.5) 298 (32.7) N/A
80–89 256 (25.7) 241 (26.4)
90–99 337 (33.8) 306 (33.6)
100 69 (6.9) 67 (7.3)
Abbreviations: EQ = EuroQol; VAS = visual analogue scale.
aData on economic activity, marital status, religion, ethnicity, day‐to‐day limitations, main language, and responsibility for children unavailable
for a minority of participants.
bData are based on results of the 2011 U.K. Census (Office for National Statistics, 2011), where available; N/A indicates that a directly comparable
question was not included in the 2011 Census.
cData comprises individuals who are separated but still legally married or in a same‐sex civil partnership.
dData includes individuals who are the surviving partner from a same‐sex civil partnership.
eCensus data reported here refers to individuals aged 16–64 only.
DEVLIN ET AL. 9within each latent group in the model. This was achieved by allowing variance for participants in different age groups to
be different within a latent group.
Models were estimated with different degrees of freedom. The most restrictive model gives different weights to the
five dimensions and assumes equal distances between levels. The second most restrictive adds different values for the
levels with a distinction between “extreme” and “unable to” (the former is the Level 5 label used for the pain/discomfort
and anxiety/depression dimensions; the latter is the Level 5 label used for the mobility, self‐care, and usual activities
dimensions). The least restrictive model has a parameter for each decrement or step away from “no problems” (Level 1)
on each dimension, thereby estimating 20 parameters (4 levels × 5 dimensions). Within these specifications, a range of
alternative models was tested to capture the possibility of interaction effects between dimensions and levels.
Twenty parametermodels that involved TTO data showed logical inconsistencies in some dimensions. In themodel used
to produce the EQ‐5D‐5L value set for England, we applied restrictions to the parameters. Specifically, the Level 2 param-
eters were estimated first, and parameters for subsequent levels were estimated by adding quadratic terms (which can be
nonnegative only, thereby ensuring that moving to worse levels of problems always resulted in an increase in disutility).
Models were estimated separately for the TTO and DCE data and then using a hybrid modelling approach with a
Bayesian regression model to combine the TTO and DCE data together (Ramos‐Goñi, Pinto‐Prades, Cabasés, &
Rivero‐Arias, 2014; Rowen, Brazier, & van Hout, 2014).
The sociodemographic composition of the sample was checked for representativeness against the general population.
The modelling approach adjusted for the age distribution of our sample to reflect the age distribution of the general
population in England. Models were estimated on data specific to selected sociodemographic groups (e.g., male
participants vs. female participants) to check for any systematic differences.
All analyses were conducted in R3.2.0 and Winbugs 14. The operating system for producing all results was Windows
10 Version 1607 for x64‐based systems. The results were produced on 10th January 2017.
The methods and analyses reported in this paper comply with the CREATE guidelines for reporting valuation studies
of multiattribute utility‐based instruments (Xie et al., 2015). The modelling methods are described in greater detail in an
accompanying paper by Feng et al. (2017).3 | RESULTS
3.1 | Sample
The interviews were conducted between November 2012 and May 2013. Of the individuals invited to take part in the study,
996 completed the valuation questionnaire, comprising TTO tasks, DCE tasks, and basic background questions, in full
(response rate = 47.7%). In accordance with the ethical approval for this study, participants who did not complete the val-
uation questionnaire in full were excluded from the analysis; hence, there are no missing TTO and DCE responses in our
dataset. Full background data were collected for 985 of the 996 participants (98.9%). Table 1 shows that, compared to the
FIGURE 4 Distribution of observed time trade‐off values [Colour figure can be viewed at wileyonlinelibrary.com]
10 DEVLIN ET AL.general population, the sample includes a larger proportion of those aged over 75 and retired individuals and a smaller pro-
portion of younger individuals and males (Office for National Statistics, 2011). The sample also includes a relatively large
proportion of individuals with health problems (approximately 14% higher than the general population).3.2 | Descriptive analysis
Figure 4 shows the distribution of observed TTO values. There is some evidence of clustering at key values on the scale
(1, 0.5, and 0) and of digit preference (where most values provided correspond to “round” numbers of years in Life A, e.g., 0,
5, and 10 years). Health states were given a value of −1 (indicating that the participants exhausted all of the lead time avail-
able to them) on 400 occasions (4.0% of all TTO observations). There are few observations (145; 1.5%) between 0 and −0.5.
We observed evidence of interviewer effects, with different proportions of worse than dead values depending on
which interviewer participants were interviewed by.
As a test of the face validity of the data, the means and medians of the TTO values were plotted against the level sum
scores of the health states. The results (see Appendix S1) show the expected negative relationship, that is, the worse the
health state, the lower the average observed value. Similarly, the proportion of those choosing A or B in the DCE tasks
was strongly correlated to the difference in level sum score between the health states, that is, the greater the difference in
severity between any two states, the more likely participants were to choose the health state with the lower level sum score.3.3 | Exclusion criteria
Twenty‐three participants (2.3%) gave all 10 health states the same value, and 61 participants (6.1%) valued 55555 no
lower than the value they gave to the mildest health state. Excluding these participants gave a core modelling dataset
of 912 participants (9,120 TTO observations). A review by Engel, Bansback, Bryan, Doyle‐Waters, and Whitehurst
(2016) shows that the exclusion of participants who give the same value to all health states or whose data contain logical
DEVLIN ET AL. 11inconsistencies is common in EQ‐5D valuation studies. Postexclusions, health states were given a value of −1 on 392
occasions (4.3% of all TTO observations).
Of the remaining individuals, 150 participants withmore than one health state valued at 0 were treated as censored on the
assumption that 0 was the lowest value they were willing to use. Censoring was also applied to 27 participants with inconsis-
tent negative data (where 55555 was given a value of 0 and more than one other health states were given negative values).3.4 | Modelling results and the value set
Of the model specifications tested, the 20‐parameter model was selected to generate the value set as it applied no assump-
tions about the parameters. When addressing the weights given to the different dimensions, the TTO data in the 5‐param-
eter model suggest weights for mobility, self‐care, usual activities, pain/discomfort, and anxiety/depression of 0.055, 0.043,
0.050, 0.081, and 0.077, respectively. The DCE data in the 5‐parameter model suggest weights of 0.332, 0.238, 0.201, 0.412,
and 0.389, respectively. Both methods suggest that pain/discomfort and anxiety/depression receive the greatest weight.
As noted in Section 2.5, we assessed the fit of models with two to 10 latent groups. The DIC statistic improved most
when moving from two to three latent groups. The predicted highest and lowest TTO values for the three‐ and 10‐group
models are similar, and the three‐group model was chosen to avoid over fitting the data. Our final model is a hybrid
model combining the TTO and DCE data and includes three latent groups. The resulting value set is presented in
Table 2. Note that in Appendix S2, we present the estimated coefficients for the latent classes, and for the dimensions
and levels, separately. However, as the latent class coefficients act to apply an adjustment across all dimensions/level
coefficients, Table 2 simplifies the presentation of the value set by reporting the coefficients for dimensions/levels after
the application of the latent class coefficients. The minimum value is −0.285 (for the worst health state, 55555) with 5.1%
of the 3,125 health states described by the EQ‐5D‐5L being valued as worse than dead. The size of the coefficients in
Table 2 reflects the relative weight placed on different sorts of health problems by our sample. For example, at the worstTABLE 2 An EQ‐5D‐5L value set for England



























The value for health state 23245 1 − (0.058 + 0.080 + 0.050 + 0.276 + 0.289) = 0.247
CODA results from final model available from the authors upon request.
aNote that the coefficients reported here are the mean coefficients from the Bayesian regressions.
12 DEVLIN ET AL.level of problems (Level 5) that can be experienced, pain/discomfort is considered to have the greatest overall impact on
HRQL (0.335), followed by anxiety/depression (0.289), mobility (0.274), self‐care (0.203), and usual activities (0.184). At
slight levels of problems (Level 2), anxiety/depression has the largest effect on HRQL, followed by pain/discomfort,
mobility, self‐care, and usual activities.
Table 2 provides a worked example of how to calculate the values for health state 23245, where the relevant
decrement for each level of problem on each dimension is subtracted from the constant. The decrements are derived
by calculating the weighted averages of the slopes for the three latent groups (not shown; see Appendix S2).3.5 | EQ‐5D and EQ‐5D‐5L value set comparisons
Table 3 compares the EQ‐5D‐5L value set with the original EQ‐5D value set (Dolan, 1997) and the crosswalk value
algorithm reported by van Hout et al. (2012). The EQ‐5D‐5L value set has a higher value for the worst possible health state
and substantially fewer worse than dead values. The decrement from the best (11111) to next best health state is smaller in
the EQ‐5D‐5L value set than in the other value sets, as might be expected given differences in number of levels and label-
ling between the instruments (e.g., 11211 describes “slight” problems performing usual activities in the five‐level instru-
ment and “some” problems in the three‐level version). Pain/discomfort has the largest overall decrement (defined as theTABLE 3 Comparison of the key characteristics of EQ‐5D‐5L values, crosswalk values, and EQ‐5D‐3L values
EQ‐5D‐5L value set Crosswalk value set EQ‐5D value set
% health states worse than dead 5.1% 26.7% 34.6%
(159 out of 3,125) (833 out of 3,125) (84 out of 243)
Preferences regarding dimensions





Usual activities Usual activities Usual activities
Value of 55555 (33333) −0.285 −0.594 −0.594
Value of 11112a 0.922 0.879 0.848
Value of 11121a 0.937 0.837 0.796
Value of 11211a 0.950 0.906 0.883
Value of 12111a 0.950 0.846 0.815
Value of 21111a 0.942 0.877 0.850
Minimum value −0.285 −0.594 −0.594
Maximum value 1 1 1
aNote that for each of the asterisked health states, the levels of problems indicated on the five‐level and three‐level versions of EQ‐5D differ, for
example, on the EQ‐5D‐5L, 11112 means no problems on any dimension except mild problems with anxiety/depression, whereas on the EQ‐5D,
11112 means no problems on any dimensions except some problems with anxiety/depression. A priori, we would expect the values for these
health states to be higher in the EQ‐5D‐5L value set than the EQ‐5D value set, which is what we observe.
bImportance is judged by the size of the coefficient for Level 5 in each dimension.
FIGURE 5 Frequency of values in the EQ‐5D (left) and EQ‐5D‐5L (right) value sets [Colour figure can be viewed at wileyonlinelibrary.
com]
DEVLIN ET AL. 13change from Levels 1 to 5), whereas usual activities has the smallest. Figure 5a,b shows that the EQ‐5D‐5L value set has a
normal distribution, in contrast to the EQ‐5D‐3L value set that was characterised by two peaks (Parkin et al., 2016).4 | DISCUSSION
We have reported a value set for the EQ‐5D‐5L, based on the preferences of a random sample of the English general
public. Such value sets promote consistency and comparability in assessments of HRQL across different patient groups.
The value set can be used to summarise EQ‐5D‐5L data collected from patients in a wide range of contexts and in the
economic evaluation of health care interventions to support resource allocation decisions.
The preferences of the English public suggest that pain/discomfort and anxiety/depression are the health problems
that are most important, whereas problems with self‐care (ability to wash or dress oneself) and usual activities (e.g.,
ability to do work, study, housework, family, or leisure activities) are less important. This reflects what members of
the public deem important and has implications for the assessment of treatments that affect different aspects of HRQL.
This is one of the first studies internationally to report a value set for the EQ‐5D‐5L. A strength of the study is that the data
have been generated using a standard protocol developed following an international programme of work (Oppe et al., 2014).
Similar studies are now underway in numerous countries worldwide, which will facilitate direct comparisons of preferences
between populations. For example, see Augustovski et al. (2016), Kim et al. (2016), Ramos‐Goñi et al. (2014), Versteegh et al.
(2016), and Xie et al. (2016) for details of studies that followed the same protocol. A further strength of our study is that it has
addressed problems with previous value sets for EQ‐5D, particularly with respect to the values for worse than dead health
states (Devlin et al., 2011; Devlin et al., 2013; Tilling et al., 2010), providing an improved basis for the use of HRQL evidence
in decision‐making. Further, innovative methods developed during the course of our study have strengthened the approach
to modelling value sets—in particular, by allowing different types of data (TTO and DCE) to bemodelled together to provide
complementary evidence on preferences, building on earlier work byOppe and vanHout (2010) and Rowen et al. (2014), and
by taking into account the nature of preference data that are “bounded” (censored), heterogeneity of participants' views in
health utilities, and heteroskedasticity of the error terms. Further details are provided in Feng et al. (2017). Although our
TTO data have face validity, a potential limitation of our study is that there is evidence of clustering at certain values and
of selective scale use. This could be linked to the relative difficulty of the TTO task, the different tasks required to value health
states better than and worse than dead in the composite TTO, and the use of an automated process to guide its administra-
tion. Interviewer effects on TTO responses may also be important given potential differences in levels of interviewer abilities
and engagement. We therefore sought to exclude problematic data that could justifiably be considered not to reflect partic-
ipants' true preferences, whilst avoiding the exclusion of inconvenient data based on subjective researcher judgements. This
involved the exclusion of some participants' data and the censoring of some values at and below 0. The alternative approach
of including all data would have meant that the assumption of a normal error distribution would need reconsidering. This in
turn would have necessitated arbitrary assumptions, potentially with less transparency than the methods we report here.We
deemed it invalid to include these data and to knowingly assume the wrong error distribution.
We tested an extensive range of model specifications in our econometric analysis, and each could feasibly have been
used to generate a value set. The choice of the model reported in this paper necessarily reflects a number of researcher
judgements about which model is “best.” For example, although we could have generated a value set based on TTO data
alone, the final value set reported here is derived from a hybrid of both TTO and DCE data, on the grounds that the two
methods provide different and complementary information about the views of the sample.
Our choice of the least restrictive (20‐parameter) model is based on two considerations. First, there are strong prior
grounds for selecting it, as it allows the values associated with different levels of problems to vary across the dimensions.
Second, the overall model statistics, that is, the DIC, suggest that it better captures the nature of the preferences of the
English general public than more restrictive models (Feng et al., 2017). Model fit was not improved by including
interaction parameters, and so there are no such interaction terms in the value set. This is in contrast to the current
EQ‐5D‐3L value set, which included the so‐called “N3 term” (a parameter capturing an additional reduction in value
to any health state with a Level 3 problem on any dimension; Dolan, 1997).
The EQ‐5D‐5L value set differs from the original EQ‐5D‐3L value set (Dolan, 1997) and the interim crosswalk
EQ‐5D‐5L tariff (van Hout et al., 2012) in important ways. First, the value for the worst state is higher, as expected, given
well‐known issues with the procedure for valuing health states worse than dead in the original value set study, which
yielded values as low as −39 that required rescaling. As well as a higher minimum value, the value set reported here also
has considerably fewer states worse than dead (5.1%, compared to around a third in the original U.K. value set). It is clear
14 DEVLIN ET AL.that using the new EQ‐5D‐5L value set will mean that some interventions will show larger QALY gains and other inter-
ventions will show smaller QALY gains than was previous assumed.
The greater descriptive sensitivity of EQ‐5D‐5L allows patients to give more refined HRQL measurement data as they
have more levels over which to describe their health. However, this increased ability to capture responses to treatment
may be counteracted by the nature of the value set reported here (Mulhern et al., 2017).
It would be possible to develop a range of value sets, based on the preferences of different population subgroups and
methodologies, for use in different contexts. Additional analyses (to be reported separately) show some differences
between the health state preferences of different age groups, such that value sets estimated from age‐specific data would
differ in important ways. However, the use of a single value set, as mandated by the NICE guidelines (NICE, 2013),
allows for consistent decision‐making across patient populations and sociodemographic groups—which is particularly
important where resource allocation decisions are concerned. See Sculpher and Gafni (2001) and Robinson and Parkin
(2002) for a debate on the use of preference subgroups.
This study raises a range of unanswered questions and areas for further research. First, the value set we have reported
is for the English population. However, some health care decisions relate to different jurisdictions. For example, NICE
decisions cover both England and Wales. The current U.K. EQ‐5D‐3L value set is used by both NICE and the Scottish
Medicines Consortium. Are the preferences of the U.K. population (i.e., including Scotland, Wales, and Northern
Ireland) consistent with the values reported here? A U.K. value set drawing on the data reported here for England,
combined with additional data collected in Scotland, Wales, and Northern Ireland, will be reported separately.
Similarly, how do the English values compare with those produced in other countries? Over a dozen international
EQ‐5D‐5L value set studies using the same protocol as used in this study are either underway or have recently
concluded, and future research can compare these in detail.
Finally, although there is evidence to support the face validity of the data used to produce this value set, there are many
remaining methodological issues that, if addressed, may help to further improve data quality. For example, changes to the
way in which the stated preference tasks and health states are presented to participants may yield improved data. There are
also a range of other promising preference elicitationmethods thatmay be used to generate values, such as DCE designs that
include an attribute for duration, and can therefore be modelled directly onto the 0 to 1 QALY scale (Bansback, Brazier,
Tsuchiya, & Anis, 2012; Mulhern et al., 2014). Although new methods in this research area will continue to be developed,
the value set reported here provides a robust and up‐to‐date basis for summarising EQ‐5D‐5L data in decision‐making.ACKNOWLEDGEMENTS
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